EUVIMEDEUVIMED entdecken
Crossref

Diaryl Diimidazopyrimidine Derivatives as Potent Inhibitors of Influenza A Virus: Synthesis, Evaluation and Docking Studies

Abburi Naga Pranathi, Devendra Nagineni, Rakesh Kumar Bollikanda, Svetlana V Belyaevskaya, Iana L Esaulkova, Vladimir V Zarubaev, Balasubramanian Sridhar, Manikanta Murahari iD, Srinivas Kantevari iD

Drug Development Research · 2025

DOI: 10.1002/ddr.70088 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2025. Verfasst von Abburi Naga Pranathi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Fluoro & Agrochemicals Division, CSIR- Indian Institute of Chemical Technology, Hyderabad, 500007, Telangana, India. Hauptthemen laut MEDLINE: Antiviral Agents, Pyrimidines, Influenza A Virus, H1N1 Subtype. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: This study was supported by Department of Science and Technology, Ministry of Science and Technology, India and Council of Scientific and Industrial Research,…, Department of Science and Technology, Ministry of Science and Technology, India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this report, we present a new series of diaryl diimidazopyrimidine derivatives 3a‐m, that have been synthesized and assessed for their in vitro antiviral activity. The derivatives were prepared through a one‐step reaction involving commercially available 2,4‐diamino‐6‐chloropyrimidine and various phenacyl bromides 2a‐m , leading to the formation of the desired diaryl diimidazo‐ pyrimidines 3a‐m with good yields. In vitro evaluations against the Influenza A H1N1 strain identified compounds 3m (SI = 73) and 3b (SI = 23) as the most potent candidates. Additionally, antimicrobial screening indicated that compounds 3d and 3j, which contain methyl and methoxy substitutions, exhibited moderate activity against Streptococcus mutans , Salmonella typhi , and Candida albicans . Molecular Docking studies of the promising compounds 3b and 3m demonstrated significant binding interactions with the M1 matrix protein (PDB ID: 5CQE) in comparison to M2 proton channel of Influenza A (PDB: 6US9), suggesting that these derivatives may be effectively targeting the M1 protein. Additionally, molecular dynamics (MD) simulations were conducted to evaluate the stability, dynamic behaviour, and binding affinity of the most potent compounds 3b and 3m. The in vitro antiviral studies, molecular docking and MD simulations data highlight the promising pharmacological potential of these analogues, paving the way for further structural optimization and development as potential antiviral agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsPyrimidinesInfluenza A Virus, H1N1 SubtypeMolecular Docking SimulationHumansMicrobial Sensitivity TestsStructure-Activity RelationshipCandida albicansMadin Darby Canine Kidney CellsStreptococcus mutansSalmonella typhiMolecular Dynamics SimulationDogsAnimals

Stichwörter der Autor:innen

antiviralsfused heterocyclesimidazopyrimidineinfluenza virusmolecular docking

Substanzen

Antiviral AgentsPyrimidines

Autor:innen und Institutionen

  • Fluoro & Agrochemicals Division, CSIR- Indian Institute of Chemical Technology, Hyderabad, 500007, Telangana, India.
  • Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, Uttar Pradesh, India.
  • Pasteur Institute of Epidemiology and Microbiology, 14 Mira str., St. Petersburg, 197101, Russia.
  • Centre for X-ray Crystallography, CSIR-Indian Institute of Chemical Technology, Hyderabad, 500007, India.
  • College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Andhra Pradesh, India.

ORCID-Profile: Manikanta Murahari, Srinivas Kantevari

Förderung

  • This study was supported by Department of Science and Technology, Ministry of Science and Technology, India and Council of Scientific and Industrial Research,…
  • Department of Science and Technology, Ministry of Science and Technology, India

Zitieren

APA

Pranathi, A. N., Nagineni, D., Bollikanda, R. K., Belyaevskaya, S. V., Esaulkova, I. L., Zarubaev, V. V., Sridhar, B., Murahari, M., & Kantevari, S. (2025). Diaryl Diimidazopyrimidine Derivatives as Potent Inhibitors of Influenza A Virus: Synthesis, Evaluation and Docking Studies. Drug Development Research. https://doi.org/10.1002/ddr.70088

Vancouver

Pranathi AN, Nagineni D, Bollikanda RK, Belyaevskaya SV, Esaulkova IL, Zarubaev VV, et al. Diaryl Diimidazopyrimidine Derivatives as Potent Inhibitors of Influenza A Virus: Synthesis, Evaluation and Docking Studies. Drug Development Research. 2025. doi:10.1002/ddr.70088

BibTeX
@article{Pranathi2025,
  author = {Pranathi, Abburi Naga and Nagineni, Devendra and Bollikanda, Rakesh Kumar and Belyaevskaya, Svetlana V and Esaulkova, Iana L and Zarubaev, Vladimir V and Sridhar, Balasubramanian and Murahari, Manikanta and Kantevari, Srinivas},
  title = {Diaryl Diimidazopyrimidine Derivatives as Potent Inhibitors of Influenza A Virus: Synthesis, Evaluation and Docking Studies},
  journal = {Drug Development Research},
  year = {2025},
  doi = {10.1002/ddr.70088}
}
Kostenlos starten →